Albert Einstein Healthcare Network

1. Intercept Pharmaceuticals, Inc. $118,608 40 payments
2. Abbott Laboratories $101,037 43 payments
3. Ipsen Pharma SAS $62,829 41 payments
4. Eko Devices, Inc. $57,488 1 payment
5. Roche Diagnostics Operations, Inc. $51,401 33 payments
6. F. Hoffmann-La Roche AG $37,980 14 payments
7. Shockwave Medical, Inc $36,776 17 payments
8. Intact Vascular, Inc. $31,863 3 payments
9. Lantheus Medical Imaging, Inc. $31,652 8 payments
10. Impulse Dynamics (USA) Inc. $31,144 19 payments

1. 1009742 $67,447 12 payments
2. Eko-Low Ef $57,488 1 payment
3. Rd005629 $51,401 33 payments
4. A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity $49,262 34 payments
5. Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) $46,333 21 payments
6. Tack Optimized Balloon Angioplasty Study of the Tack Endovascular in Femoropoliteal Arteries (TOBA II) $31,363 2 payments
7. Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy $31,144 19 payments
8. Ocrelizumab in Patients With RMS $30,780 9 payments
9. Hemodynamic-GUIDEd Management of Heart Failure $27,125 13 payments
10. Randomized study of the Shockwave Medical Peripheral Lithoplasty System used in combination with DCB versus standard balloon angioplasty used in combination with DCB to treat moderate and severely calcified femoropopliteal arteries (Disrupt PAD III) $25,801 14 payments

1. Patient care $48,672 13 payments
2. Other $5,308 1 payment
3. Overhead $500 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.